Biotech Values

[iwfal]

DNDN’s executives repeatedly boast that Provenge “fundamentally changes the treatment of prostate cancer” when, in actuality, Provenge changes almost nothing for patients who suffer from the disease.

I do think that Provenge does create some paradigm shifts:

a) It probably has the least SAEs of any solid metastatic tumor treatment in existance. (If there is some other treatment as benign I would like to be corrected.)

b) It is the first cancer vaccine. As such it will allow people to better understand how it works and build the next one - and improve on it.

FWIW.